Quarterly report pursuant to Section 13 or 15(d)

10. Segment and Geographic Information

v3.3.1.900
10. Segment and Geographic Information
 9 Months Ended
Dec. 31, 2015
Segment Reporting [Abstract]  
Segment and Geographic Information

The Company generates product revenues from wound care products that are sold into the human and animal healthcare markets, and the Company generates service revenues from laboratory testing services, which are provided to medical device manufacturers.

 

The Company operates a single segment business for product revenues, which consists of three geographical sales territories as follows:

 

    Three Months     Nine Months  
    Ended     Ended  
    December 31,     December 31,  
Geographic region   2015     2014     2015     2014  
United States   $ 1,010,000     $ 647,000     $ 2,983,000     $ 1,358,000  
Latin America     1,261,000       1,076,000       4,085,000       3,336,000  
Europe and Rest of World     1,202,000       751,000       2,725,000       1,977,000  
      3,473,000       2,474,000       9,793,000       6,671,000  
Product license fees and royalties     120,000       555,000       906,000       2,601,000  
Total product related revenues   $ 3,593,000     $ 3,029,000     $ 10,699,000     $ 9,272,000  

 

The following table shows the Company’s product license fees and royalties revenues by partner:

 

    Three Months     Nine Months  
    Ended     Ended  
    December 31,     December 31,  
Partner   2015     2014     2015     2014  
Exeltis (formerly Quinnova)   $ 44,000     $ 54,000     $ 201,000     $ 361,000  
Innovacyn     –       123,000       29,000       1,110,000  
Laboratorios Sanfer (formerly More Pharma)     76,000       378,000       676,000       1,130,000  
Total product license fees and royalties   $ 120,000     $ 555,000     $ 906,000     $ 2,601,000  

 

The Company’s service revenues amounted to $227,000 and $189,000 for the three months ended December 31, 2015 and 2014, respectively.

 

The Company’s service revenues amounted to $855,000 and $602,000 for the nine months ended December 31, 2015 and 2014, respectively.